Hepatoblastoma (Pediatric)

Hepatoblastoma (Pediatric)

News & Stories

The Rogel Cancer Center building
News Release

U-M researcher receives Cancer Grand Challenges funding to crack the dark proteome of cancer

John Prensner, MD, PhD at University of Michigan Health C.S. Mott Children’s Hospital and research member at the Rogel Cancer Center is part of a research team called ILLUMINE which will receive a Cancer Grand Challenges award.
close up of white clear circles with pale ivory in middle
Health Lab

Encapsulated ovarian donor tissue restores ovarian function in mice

University of Michigan researchers have demonstrated that donated ovarian tissue can produce natural hormone cycles in mice, with the aim of restoring female hormone cycles for pediatric cancer survivors.
Triplet babies in a hospital crib
Health Lab

Rare infant triplet overcomes one-in-a-million type of liver cancer

Josephine “JoJo” Wells, a spontaneous triplet, was diagnosed with rare hepatoblastoma at nine months old and treated with surgery and chemotherapy.
Abhijit Parolia, PhD in his laboratory
News Release

Parolia Lab Receives Grant to Fund New Pediatric Cancer Research

Alex's Lemonade Stand Foundation has awarded a grant supporting the work of Abhijit Parolia, PhD, and his lab, which currently studies how changes in the genome’s regulatory machinery can drive cancer.
parents posing in selfie up close with kid in front of them
Health Lab

4-year-old pediatric brain cancer patient wins over his care team with cheerful personality

Pediatric cancer patient at Michigan Medicine was diagnosed with ATRT and underwent chemotherapy and radiation. Four years later, he’s doing well.
brain scan on computer
Health Lab

FDA clears new DMG treatment: What it means for a deadly pediatric brain tumor

Diffuse midline gliomas are aggressive tumors that begin in the brain or spinal cord. It is universally fatal, and patients typically live for nine to 15 months after diagnosis. The FDA has approved ONC201 (dordaviprone) to treat recurrent H3K27M-mutant diffuse glioma. It's the first-ever FDA-approved treatment for this disease.